Entera Bio Ltd. (ENTX): Shareholders' Equity
$13.10M
As of 2025-12-31
$7.27M
As of 2026-06-30
+3.7%
3-year compound annual growth
+11.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.10M | +62.1% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $8.08M | -22.2% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $10.39M | -11.6% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $11.75M | -47.9% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $22.57M | +200.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $7.51M | n/a | 2022-03-08, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $13.10M | +62.1% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $23.52M | -26.7% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $5.59M | -78.2% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$9.78M | n/m |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$1.10M | n/m |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | -$514.9K | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $67.48M | -3.6% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.51M | +18.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $45.39M | -45.3% |
Compare ENTX, INMB, SNTI, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗